SCHEMBL2331745

SCHEMBL2331745

CN(CCN1CCC(c2ccccc2)(N2CCCC2)CC1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 14/20 0.56
SIGMAR1 Q99720 3/20 0.49
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
CYP2B6 P20813 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
PRCP P42785 1/20 0.49
SLC6A3 Q01959 1/20 0.49
GRIN1 Q05586 1/20 0.49
KCNH2 Q12809 1/20 0.49
GRIN2A Q12879 1/20 0.49
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
GRIN3A Q8TCU5 1/20 0.49
OPRM1 P35372 2/20 0.48
OPRD1 P41143 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2333142 0.99 HRH3 (0.55) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
SCHEMBL28026045 0.91 HRH3 (0.55) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
SCHEMBL2831968 0.86 HRH3 (0.50) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
Triaziquone SCHEMBL2333140 0.84 HRH3 (0.43) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
SCHEMBL2333546 0.83 HRH3 (0.47) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
SCHEMBL2333169 0.82 HRH3 (0.54) HRH3OPRM1
SCHEMBL3409607 0.81 ALDH1A1 (0.46) HRH3
SCHEMBL28026517 0.80 KDM4E (0.45) HRH3
SCHEMBL3404217 0.80 HRH3 (0.44) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6
SCHEMBL3410705 0.79 HRH3 (0.43) HRH3SIGMAR1GRIN2DGRIN3BCYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
EP-2356101-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2011-08-17 EP disclosed
EP-2254883-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2010-12-01 EP disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
WO-2010046109-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2010-04-29 WO disclosed
WO-2009103552-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2009-08-27 WO disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215828-A1 Substituted indole derivatives IDO1, IDO2, TPH1 HRH3 405/4885SIGMAR1 235/4885GRIN2D 1547/4885
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS HRH3 247/4885SIGMAR1 1220/4885GRIN2D 2461/4885
US-20130116283-A1 Substituted indole derivatives IDO1, IDO2, TPH1 HRH3 405/4885SIGMAR1 235/4885GRIN2D 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.